Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Focus on Europe

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Published Online June 21, 2007
Science DOI: 10.1126/science.1143780

Reports

Submitted on April 13, 2007
Accepted on June 8, 2007

Sirtuin 2 Inhibitors Rescue {alpha}-Synuclein-Mediated Toxicity in Models of Parkinson's Disease

Tiago Fleming Outeiro 1, Eirene Kontopoulos 2, Steve Altman 3, Irina Kufareva 4, Katherine E. Strathearn 5, Allison M. Amore 3, Catherine B. Volk 5, Michele M. Maxwell 3, Jean-Christophe Rochet 5, Pamela J. McLean 1, Anne B. Young 3, Ruben Abagyan 4, Mel B. Feany 2, Bradley T. Hyman 1, Aleksey Kazantsev 3*

1 Alzheimer's Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA; MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA.
2 Harvard Medical School and Brigham and Women's Hospital, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Harvard New Research Building, Room 630, 77 Louis Pasteur Avenue, Boston, MA 02115, USA.
3 MassGeneral Institute for Neurodegenerative Disease, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA.
4 Department of Molecular Biology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.
5 Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907-2091, USA.

* To whom correspondence should be addressed.
Aleksey Kazantsev , E-mail: akazantsev{at}partners.org

The sirtuins are members of the histone deacetylase family of proteins that participate in a variety of cellular functions and play a role in aging. Here, we identified a potent inhibitor of sirtuin 2 (SIRT2), and found that inhibition of SIRT2 rescued {alpha}-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. Genetic inhibition of SIRT2 via siRNA similarly rescued {alpha}-synuclein toxicity. Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1.
H. Catoire, M. Y. Pasco, A. Abu-Baker, S. Holbert, C. Tourette, B. Brais, G. A. Rouleau, J. A. Parker, and C. Neri (2008)
Hum. Mol. Genet. 17, 2108-2117
   Abstract »    Full Text »    PDF »
Quantitative Proteomics of a Presymptomatic A53T {alpha}-Synuclein Drosophila Model of Parkinson Disease.
Z. Xun, R. A. Sowell, T. C. Kaufman, and D. E. Clemmer (2008)
Mol. Cell. Proteomics 7, 1191-1203
   Abstract »    Full Text »    PDF »
Monoubiquitylation of {alpha}-Synuclein by Seven in Absentia Homolog (SIAH) Promotes Its Aggregation in Dopaminergic Cells.
R. Rott, R. Szargel, J. Haskin, V. Shani, A. Shainskaya, I. Manov, E. Liani, E. Avraham, and S. Engelender (2008)
J. Biol. Chem. 283, 3316-3328
   Abstract »    Full Text »    PDF »
Possible New Treatment Strategy for Parkinson Disease.
(2007)
Journal Watch (General) 2007, 3
   Full Text »



ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products


Science. ISSN 0036-8075 (print), 1095-9203 (online)